Billionaire-backed TCR startup scores its first marquee industry alliance
SAN FRANCISCO — A Bay Area startup out to create a next-gen player in TCRs has just hit a key milestone following its recent debut, inking its first big alliance with a big-name pharma while also bringing in some added insights from clinical operations that can help shape their work.
Initially ramped up in stealth back in 2017 with early backing from Sean Parker and the Parker Institute for Cancer Immunotherapy, 3T Biosciences announced a $40 million A round a few months ago. Now, CEO Stefan Scherer has forged a partnership with Boehringer Ingelheim, a large German pharma that remains private.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.